Many studies have demonstrated that the differentiation of macrophages and ratio of M1/M2 macrophages are related to tumor therapy, in which the M1 macrophage phenotype is classified to have an anti‐tumor effect and M2 has the opposite effect.[36, 37, 38] We previously showed that the status of PBRM1 may be related to RCC immunotherapy.[33] Our data demonstrate that alterations in PBRM1 particularly promote polarization of M1 macrophages, thereby inducing remodeling of the immune microenvironment and augmenting immunotherapeutic effects. This evidence concerns the gene PBRM1 and renal cell carcinoma.